Oklahoma SB1344 creates the Insulin Access and Affordability Program to increase access to affordable insulin.

Oklahoma SB1344 establishes the Insulin Access and Affordability Program, administered by the State Department of Health, to enhance access to affordable insulin and address shortages. The bill requires the manufacturer to produce a low-cost, fast-acting biosimilar insulin, with financial support contingent on this commitment. The agreement includes estimated savings for residents and payors, repayment provisions if the insulin is not produced, and annual reporting. The act becomes effective July 1, 2026, with an emergency declaration for immediate implementation.

Oklahoma SB1344 creates the Insulin Access and Affordability Program to increase access to affordable insulin.

Oklahoma SB1344 establishes the Insulin Access and Affordability Program, administered by the State Department of Health, to enhance access to affordable insulin and address shortages. The bill requires the manufacturer to produce a low-cost, fast-acting biosimilar insulin, with financial support contingent on this commitment. The agreement includes estimated savings for residents and payors, repayment provisions if the insulin is not produced, and annual reporting. The act becomes effective July 1, 2026, with an emergency declaration for immediate implementation.